Inositol in Preventing Lung Cancer in Patients With Bronchial Epithelial Dysplasia Who Are Current or Former Smokers

Phase 1CompletedNCT00061997

British Columbia Cancer Agency

Overview

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Inositol may be effective in preventing the development of lung cancer in patients with bronchial epithelial dysplasia. PURPOSE: This phase I trial is studying the side effects and best dose of inositol in preventing lung cancer in current or former smokers with bronchial epithelial dysplasia.

OBJECTIVES: * Determine the safety of inositol for the prevention of lung cancer in patients with bronchial epithelial dysplasia who are current or former smokers. * Determine the potential efficacy of this drug in regression of existing dysplastic lesions or prevention of appearance of new dysplastic lesions in these patients. * Determine whether intake of this drug can facilitate smoking cessation in patients who are current smokers. OUTLINE: This is a dose-escalation study. Patients receive oral inositol twice daily. Treatment continues for 1 or 3 months in the absence of disease progression or unacceptable toxicity. Cohorts of 3-12 patients receive escalating doses of inositol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 12 patients experience dose-limiting toxicity. Once the MTD is determined, 10 patients are treated with inositol twice daily at the MTD for 3 months in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month. PROJECTED ACCRUAL: A total of 3-28 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Purpose

PREVENTION

Conditions

Lung Cancer Precancerous Condition

Interventions

inositolDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 40 YearsMax age: 74 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of persistent bronchial dysplasia despite regular twice-daily treatment with inhaled budesonide for 6 or 12 months on protocol BCCA-CIC-98-37 * Current or former smokers who have smoked at least 30 pack years * Sputum cells showing AIC atypia by computer-assisted image analysis * At least 2 abnormal sites on fluorescence bronchoscopy (red/green ratio at least 0.45) suspicious for bronchial dysplasia * At least 1 site confirmed by bronchial biopsy * Solitary dysplastic lesion allowed provided the diameter is greater than 1.5 mm * No invasive cancer on bronchoscopy or abnormal low-dose spiral CT scan suspicious for lung cancer PATIENT CHARACTERISTICS: Age * 40 to 74 Performance status * ECOG 0-1 Life expectancy * Not specified Hematopoietic * Hematologic function normal * No bleeding disorder Hepatic * Liver function normal * Liver enzymes no greater than upper limit of normal Renal * Renal function normal Cardiovascular * No unstable angina * No congestive heart failure Pulmonary * No acute or chronic respiratory failure * No acute bronchitis or pneumonia within the past month Other * Fasting glucose less than 144 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Willing to have a bronchoscopy * No schizophrenia * No bipolar disorder * No diabetes * No known reaction to topical xylocaine * No other medical condition that would jeopardize patient safety during study participation PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy Endocrine therapy * Not specified Radiotherapy * No prior radiotherapy Surgery * No prior surgery for lung cancer Other * No concurrent lithium

Locations (1)

British Columbia Cancer Agency - Vancouver Cancer Centre

Vancouver, British Columbia, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.